Market Closed -
Other stock markets
|
After market 12:42:24 | |||
17.3 USD | -39.47% | 0.439 | -97.46% |
12:41pm | Needham Downgrades Cara Therapeutics to Hold From Buy | MT |
12:40pm | HC Wainwright Downgrades Cara Therapeutics to Neutral From Buy | MT |
Sales 2024 * | 6.21M 8.55M | Sales 2025 * | 6.3M 8.66M | Capitalization | 37.15M 51.12M |
---|---|---|---|---|---|
Net income 2024 * | -73M -100M | Net income 2025 * | -64M -88.06M | EV / Sales 2024 * | 9.44 x |
Net Debt 2024 * | 21.5M 29.58M | Net Debt 2025 * | 78.9M 109M | EV / Sales 2025 * | 18.4 x |
P/E ratio 2024 * |
-0.56
x | P/E ratio 2025 * |
-0.83
x | Employees | 55 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 84.75% |
Latest transcript on Cara Therapeutics, Inc.
1 day | -97.49% | ||
1 week | +2,416.73% | ||
Current month | +2,603.12% | ||
1 month | +2,247.35% | ||
3 months | +1,811.60% | ||
6 months | +1,391.38% | ||
Current year | +2,285.22% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 54 | 18-08-05 | |
Ryan Maynard
DFI | Director of Finance/CFO | 54 | 22-09-11 |
Scott Terrillion
CMP | Compliance Officer | 61 | 16-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Martin Vogelbaum
CHM | Chairman | 60 | 10-06-30 |
Jeffrey Ives
BRD | Director/Board Member | 73 | 14-07-15 |
Helen Boudreau
BRD | Director/Board Member | 58 | 23-08-01 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-12 | 0.6582 | +0.40% | 6,214 |
24-06-11 | 0.6556 | +1.31% | 7,648 |
24-06-10 | 0.6471 | +4.20% | 1,847 |
24-06-07 | 0.621 | -5.78% | 11,579 |
24-06-06 | 0.6591 | -4.12% | 3,749 |
Delayed Quote London S.E., November 09, 2021 at 09:36 am
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.46% | 91.38B | |
-3.16% | 38.68B | |
-9.80% | 33.58B | |
+72.31% | 27.84B | |
-13.11% | 16.05B | |
-3.01% | 13.48B | |
-9.38% | 11.73B | |
+172.59% | 10.74B | |
-49.44% | 10.39B |
- Stock Market
- Equities
- CARA Stock
- 0HTC Stock